Skip to Content
Merck
All Photos(1)

Key Documents

569427-U

Supelco

Discovery® C8 (5 µm) HPLC Columns

L × I.D. 12.5 cm × 4.6 mm, HPLC Column

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Discovery® C8 HPLC Column, 5 μm particle size, L × I.D. 12.5 cm × 4.6 mm

material

stainless steel column

Agency

suitable for USP L7

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

7.5% Carbon loading

parameter

≤70 °C temp. range
400 bar pressure (5801 psi)

technique(s)

HPLC: suitable
LC/MS: suitable

L × I.D.

12.5 cm × 4.6 mm

surface area

200 m2/g

surface coverage

3.4 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical base material
fully porous particle

matrix active group

C8 (octyl) phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

reversed phase

Looking for similar products? Visit Product Comparison Guide

Features and Benefits

  • Excellent reproducibility
  • Faster separation of strongly hydrophobic analytes than C18 columns
  • Stable, low-bleed LC-MS separations
  • Exceptional peak shapes for basic and acidic compounds
  • Compatible with low organic/highly aqueous mobile phases

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hugo M Botelho et al.
Scientific reports, 5, 9038-9038 (2015-03-13)
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of
Bo-Rui Kang et al.
Bioorganic & medicinal chemistry letters, 25(24), 5808-5812 (2015-11-08)
2-Benzylisoquinolin-1(2H)-ones has been proposed as vasodilative agents on the basis of scaffold hopping. In the present study, a series of 2-benzylisoquinolin-1(2H)-ones were synthesized. Their vasodilative effects were evaluated by wire myograph on isolated rat mesenteric arterial ring induced contraction with
Scott C Bell et al.
Pharmacology & therapeutics, 145, 19-34 (2014-06-17)
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the opportunity to enhance CF transmembrane conductance regulator (CFTR) protein synthesis and/or function. CFTR
H Jayasuriya et al.
Journal of natural products, 55(5), 696-698 (1992-05-01)
Bioassay-directed fractionation of a Chinese medicinal plant, Polygonum cuspidatum (Polygonaceae), has led to the discovery of an anthraquinone, emodin [1], as a strong inhibitor of a protein tyrosine kinase (p56lck) partially purified from bovine thymus. Comparison of the IC50 values
J Reniers et al.
European journal of medicinal chemistry, 46(12), 6104-6111 (2011-10-25)
Previous studies on 5H-indeno[1,2-c]pyridazin-5-one derivatives as inhibitors of MAO-B revealed that it was possible to increase the MAO-B inhibitory potency of 5H-indeno[1,2-c]pyridazin-5-ones by substituting the central heterocycle in the 3-position or C-8 with lipophilic groups which occupy the substrate cavity

Related Content

Discovery C18 and C8 HPLC Columns products offered

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service